To further enhance the therapeutic efficacy of ELP-based nanotechnology in treating AML, this study reports the development of a novel dual-targeting modality that potently targets both CD99 and FLT3 by co-assembling equal amounts of CD99-A192 and FLT3-A192 proteins. The gene discussed is CD99; the disease is acute myeloid leukemia.